Influx Flow Cytometer

描述（由申请人提供）：NIH基金被要求购买一个BD涌入细胞分选器，将放置在波士顿马萨诸塞州总医院（MGH） PI的870平方英尺的研究实验室。内流是一个6激光仪器，这是一个大大改进，完善和一个更强大的细胞分选比，它将取代，FACS优势。Vantage最初设计于20世纪90年代，并于2000年由PI与NCRR基金购买；该仪器光学台上的四个离子气体激光器中有两个已经使用了25年以上。由于它的年代年龄，Vantage越来越难以维护。更关键的是，从工程和技术的角度来看，它不再提供我们的用户群所需要的必要的荧光灵敏度、蜂窝吞吐量和高容量6路分选能力。此外，快速增长的转化研究重点强调了对人类细胞安全，生物含量分选能力的需求，超出了我们当前分选平台的能力。因此，要求的内流将额外配置贝克II类A2型认证HEPA过滤生物安全罩，这将为操作人员和当地环境提供更大的保护。所要求的内流将被放置在PI成熟的流式细胞术核心中，该核心已经成功运作了近30年。与细胞生物学、免疫学、遗传学、分子生物学、传染病、肿瘤学和干细胞研究相关的各种研究都将受益于PI设施中放置的该仪器。PI在利用多色细胞术进行研究和临床工作方面有着良好的记录，并有文件表明所要求的仪器将为MGH的研究用户群提供必要的资源。该仪器最初将为来自9个部门和众多MGH单位的28名主要研究人员组成的多学科小组提供服务，代表78个NIH资助的拨款总额超过4480万美元。涌入将进一步使MGH的整个研究界受益，他们目前缺乏用于NIH资助工作的现代细胞分选器。整个医院大约有1000名PI， NIH的预算约为3.25亿美元。自1982年以来，PI一直是MGH研究界的一部分，他的实验室是MGH所有研究人员唯一可以轻松使用的实验室。实验室拥有技术娴熟的操作人员，他们与PI共同代表了近60年的流式细胞术经验。该实验室得到病理科和MGH管理部门的财政支持，并得到大学生物安全办公室对本报告中概述的项目的批准。

DESCRIPTION (provided by applicant): NIH funds are requested to purchase a BD Influx cell sorter that will be placed in the PI's 870 ft2 research laboratory at Massachusetts General Hospital (MGH) in Boston. The Influx is a 6- laser instrument that is a vastly improved, refined and a far more powerful cell sorter than that it will replace, the FACS Vantage. The Vantage was initially designed in the 1990s and purchased by the PI with NCRR funds in 2000; two of the four ion-gas lasers on this instrument's optical bench are over 25 years old. Due to its chronologic age, the Vantage is increasingly difficult to maintain. Far more critically, from an engineering and technological perspective it no longer offers the necessary fluorescence sensitivity, cellular throughput and high capacity 6-way sorting ability that our user base requires. Also, a rapidly increasing translational research emphasis has accentuated the need for safe, bio-contained sorting capabilities of human cells beyond the capacity of our current sorting platform. Thus, the requested Influx will be configured additionally with a Baker class II Type A2 certified HEPA filtered biosafety hood that will provide far greater protection to the operator and local environment. The requested Influx will be placed in the PI's well established Flow Cytometry Core which has been in successful operation for almost 30 years. A wide variety of studies related to cell biology, immunology, genetics, molecular biology, infectious disease, oncology and stem cell research will all benefit from the placement of this instrumentation in the PI's facility. The PI has an established track record in utilizing polychromatic cytometry for both research and clinical work and documents that the requested instrument will provide an essential resource to the needs of the research user base at MGH. This instrument will initially serve a multidisciplinary group of 28 primary investigators from 9 departments and numerous MGH Units, representing 78 NIH funded grants totaling over 44.8 million dollars. The Influx will further benefit the entire research community at MGH, who presently lack a modern cell-sorter for their NIH funded work. The entire hospital of approximately 1000 PI's has a NIH budget of about $325 million dollars. The PI has been part of the MGH research community since 1982, and his laboratory has been the only one easily available to all investigators at MGH. The laboratory has a highly skilled operator, who along with the PI collectively represents almost 60 years of well-documented experience in flow cytometry. The laboratory has the financial support of both the Department of Pathology and MGH administration and approval of the University Biosafety office for the projects outlined in this submission.